Texture and Colour Enhancement Imaging (TXI) Versus Dye Chromoendoscopy for Dysplasia Detection in IBD Surveillance.
- Sponsor
- London North West Healthcare NHS Trust
- Study ID
- NCT07208214
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- TXI — DIAGNOSTIC_TESTParticipants allocated to the "TXI" group undergo withdrawal using Texture and Colour Enhancement Imaging, while those in the "Dye" group receive withdrawal with Dye chromoendoscopy. Both procedures follow standardized protocols outlined in the study design.
Study Details
In individuals with inflammatory bowel disease (IBD), bowel cancer can develop from abnormal cell changes (dysplasia). Regular colonoscopies are recommended to identify these early changes, which can be difficult to detect because they are often small and subtle. Dye-based imaging has been used to improve detection, but it requires additional preparation and time. Texture and Colour Enhancement Imaging (TXI) is a newer method available in clinical practice that adjusts brightness, colour, and texture on high-definition cameras. This study will compare TXI with dye-based imaging to assess which approach detects precancerous changes more effectively in patients with IBD.
Key Dates
- Start date
- Oct 1, 2025
- Status verified
- Sep 2025
- Primary completion
- Jul 1, 2027
- Completion
- Jul 1, 2027
Study Design
- Enrollment
- 242 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- DIAGNOSTIC
Arms
- Active Comparator: TXIParticipants allocated to the "TXI" group undergo withdrawal using Texture and Colour Enhancement Imaging
- Other: DyeParticipants allocated in the "Dye" group receive withdrawal with Dye chromoendoscopy.
Primary Outcome Measure
To compare the proportion of patients with at least 1 dysplastic lesion detected using TXI compared with dye chromoendoscopy [ Time Frame: 6 months ]
Central Contacts
- Jonathan Landy, Consultant Gastroenterologist020 8869 544
Related Studies
- Ex-vivo Confocal Imaging and Proteomic Profiling to Determine Treatment Response in Children With IBDNot Yet Recruiting · Cook Children's Health Care System · Arlington, Texas
- Evaluation of the SMART IBD App in Pediatric IBDRecruiting · Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio
- Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBDRecruiting · Connecticut Children's Medical Center · Hartford, Connecticut